Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsies

21 Feb 2018

Abstract excerpt

Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, leading to overdiagnosis and overtreatment. Aberrant promoter hypermethylation of specific genes has been suggested as novel candidate biomarkers for PC that may improve diagnosis and prognosis. We here analyzed ST6GALNAC3 and ZNF660 promoter methylation in prostate tissues, and ST6GALNAC3, ZNF660, CCDC181, and HAPLN3 promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29465788
DOI: 10.1002/1878-0261.12183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsiesPMID 29465788Read ↗

Prognostic DNA Methylation Markers for Prostate CancerSemantic proximity Read ↗

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate CancerSemantic proximity Read ↗

A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancerSemantic proximity Read ↗

Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate CancerSemantic proximity Read ↗

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker PotentialSemantic proximity Read ↗

ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancerSemantic proximity Read ↗

Prediction of Prognosis in Patients with Prostate Cancer by DNA Methylation ClassificationSemantic proximity Read ↗

Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer.Semantic proximity Read ↗

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalitySemantic proximity Read ↗

Integrating Multi-Omics Data to Uncover Prostate Tissue DNA Methylation Biomarkers and Target Genes for Prostate Cancer Risk.Semantic proximity Read ↗

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and PrognosisSemantic proximity Read ↗

Subtypes of m6A RNA Modification Defines Tumor Microenvironment, Immunotherapy and Pharmacogenomic Landscape in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.